Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Hemant M Kocher1,2,3,4, Bristi Basu5, Fieke E M Froeling6,7

  • 1Centre for Tumour Biology, Barts Cancer Institute-A CRUK Centre of Excellence, Queen Mary University London, London, EC1M 6BQ, UK. h.kocher@qmul.ac.uk.

Nature Communications
|September 25, 2020
PubMed

Insights

All-trans-retinoic-acid (ATRA) combined with chemotherapy is safe for advanced pancreatic cancer. This combination shows promising overall survival and potential for stromal modulation in pancreatic ductal adenocarcinoma (PDAC) patients.

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Pre-clinical studies suggest all-trans-retinoic-acid (ATRA) can reprogram pancreatic stellate cells, suppressing pancreatic ductal adenocarcinoma (PDAC) growth.
  • Pancreatic stellate cells play a crucial role in the tumor microenvironment, promoting PDAC progression.

Purpose of the Study:

  • To evaluate the safety and tolerability of re-purposing ATRA as a stromal-targeting agent in combination with gemcitabine-nab-paclitaxel chemotherapy in patients with advanced PDAC.
  • To determine the recommended phase 2 dose (RP2D) for this combination therapy.
  • To explore potential pharmacodynamic markers of stromal modulation and predictive biomarkers of response.

Main Methods:

  • A phase Ib, dose escalation and expansion trial (n=27) using a two-step adaptive continual re-assessment method design.
  • Patients received gemcitabine-nab-paclitaxel with escalating doses of ATRA.
  • Primary outcome: Maximum Tolerated Dose (MTD) and RP2D. Secondary outcomes: ATRA pharmacokinetics, overall survival, and exploratory pharmacodynamics (DW-MRI, pentraxin 3 levels).
  • Biomarker analysis included baseline expression of retinoid transport proteins (FABP5, CRABP2).

Main Results:

  • The RP2D was established as the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel plus ATRA (45 mg/m² orally, days 1-15/cycle).
  • The most frequent dose-limiting toxicity was grade 4 thrombocytopenia (n=2).
  • Median overall survival for the RP2D-treated evaluable population (n=15) was 11.7 months.
  • Exploratory studies indicated stromal modulation via changes in apparent diffusion coefficient (DW-MRI) and pentraxin 3 levels.
  • Baseline FABP5 and CRABP2 expression may predict response.

Conclusions:

  • Re-purposing ATRA in combination with gemcitabine-nab-paclitaxel is safe and tolerable for patients with advanced, unresectable PDAC.
  • The combination demonstrates promising overall survival and evidence of stromal modulation.
  • This combination warrants further evaluation in a phase II randomized controlled trial for locally advanced PDAC.

Related Concept Videos